The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease
Haukeland University Hospital · University of Bergen · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
294
total citations
- FWCI
- 32.06
- Percentile
- 100%
- References
- 76
Citations per year
Authors
20- BBBrage Brakedal
Haukeland University Hospital, University of Bergen
- CDChristian Dölle
Haukeland University Hospital, University of Bergen
- FRFrank Riemer
Haukeland University Hospital
- YMYilong Ma
Feinstein Institute for Medical Research, Neurosciences Institute, Center for Neurosciences
- GSGonzalo S. Nido
Haukeland University Hospital, University of Bergen
Topics & keywords
Topics
Keywords
- NAD+ kinase
- Nicotinamide adenine dinucleotide
- Neuroprotection
- Nicotinamide phosphoribosyltransferase
- Metabolome
- Parkinson's disease
- Medicine
- Cerebrospinal fluid
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.